BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 1, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2009

View Archived Issues

Astellas Pharma discloses TrkA tyrosine kinase inhibitors for the treatment of urinary conditions

Read More

Janssen describes prokineticin-1 receptor antagonists for the treatment of gastrointestinal diseases

Read More

Hsp27 inhibitor OGX-427 well tolerated, affects tumor markers in phase I study

Read More

AVI BioPharma and CFI sign additional drug development contract for AVI-5038 in DMD

Read More

Boehringer Ingelheim discovers phosphodiesterase 4B inhibitors for the treatment of COPD

Read More

DSMB recommends continuation of phase III trial comparing Avexa's ATC to 3TC in HIV

Read More

Novel sphingosine-1-phosphate receptor agonists described by Pfizer

Read More

Novel calcium channel blockers emerge from Pfizer R&D

Read More

Belatacept shows immunosuppressant activity in phase II/III studies in kidney transplant recipients

Read More

NIAID initiates trial evaluating AEOL-10150 for treating radiation exposure

Read More

EyeGate Pharma reports that EGP-437 improves signs and symptoms of dry eye

Read More

Pharming receives EMEA agreement on pediatric investigation plan for Rhucin

Read More

CNTO-328 shows acceptable safety and promising activity in phase II trials in CRPC and MM patients

Read More

Ancora receives phase I SBIR grant from NIH to research SMA vaccine

Read More

ACT signs exclusive license for anticancer therapeutic from University of Louisville

Read More

Cytopia completes 3-year research term under 2006 collaboration with Novartis

Read More

Somaxon resubmits NDA for insomnia drug Silenor to FDA

Read More

CDA-1 and CDB-1 show efficacy in phase II study in C. difficile diarrhea

Read More

Phase II data on olaparib in breast, ovarian cancer reported at ASCO

Read More

Single i.v. dose of BG-9928 displays minimal effect on cardiac conduction in healthy volunteers

Read More

Nebivolol does not affect hemoglobin levels in chronic heart failure patients; SENIORS data suggest

Read More

Rolofylline fails to demonstrate efficacy for acute heart failure in phase III PROTECT study

Read More

PolyMedix initiates dosing in second phase I systemic antibiotic trial

Read More

Anadys initiates strategic restructuring to focus on development of ANA-598 in hepatitis C

Read More

FDA grants orphan drug designation to Delcath's melphalan for neuroendocrine tumors

Read More

Lpath receives grant from the NCI to use for lead candidate Asonep

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 30, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing